The site of LA’s top rated and increasingly popular birthday party packages, where parents can really treat their kids to a celebration to be remembered, Giggles N’ Hugs has quickly won favor with LA families as the premier destination for nutritious, delicious food, as well as healthy play and activities for the kids (focus is 1 to 10 age group). Parents can relax in an elegant casual dining area that is adjacent to a fully-equipped play area and enjoy scrumptious selections from a menu centered squarely on gourmet organic food options. From build-your-own pizzas and gourmet goat cheese pizzas with sun-dried tomatoes, eggplant and fresh basil, to a wide selection of fresh salads, pasta dishes, sandwiches, wraps, paninis, and appetizers, GIGL aims to please, with a top-shelf menu that will satisfy health-conscious parents, and kids alike.

By offering patrons enticing deals, such as themed parties that run the gamut from cartoon characters and super heroes, to princesses and sports, as well as membership deals for frequent visitors, including such benefits as 10 percent off beverages, food and retail purchases, Giggles N’ Hugs has had great success cultivating local consumer’s receptivity to its innovative business model. With three primary locations in upscale shopping destinations around LA, including Century City Mall, Glendale Galleria and the Topanga Canyon Mall, GIGL’s unique proposition of allowing parents to drop kids off so they can go shopping, is already proving itself to be a real gold mine. With national and even international expansion in the cards for GIGL, this ingenious combo of custom-made 2,000 plus square-foot indoor play areas with the capacity to act as the first and only restaurant in LA where parents can safely leave their children to go shopping, paying only a nominal entry fee for the child, content in the knowledge that the children will be well looked after by GIGL’s trained staff and kept entertained by numerous activities and the wonderful active play area, is a huge advantage for the company moving forward.

Already in talks with some of the biggest mall owners across the country, GIGL is the kind of synergistic tenant that malls want to have, precisely because of winning features like the drop-off service, and the basic model is also quite attractive. Think about it: there basically isn’t a competing class of restaurant that caters to kids in this way, with a colorful, attractive and gigantic play area full of climbers, castles, dragons, pirate ships and numerous fun toys. A place where a full schedule of activities every half hour, from face painting or arts and crafts, to puppet shows and live music by premium children’s entertainers, keeps toddlers busy so that their parents can relax and enjoy a quality meal, unwind with a glass of wine and talk about their day, or just watch the game. This dual approach, focused on the children, but obviously also catering to adults, reinforced by a healthy menu that is devoid of artificial cheese, potatoes, or GMO cooking oils and the like, is an idea whose time has come.

Parents no longer need to worry about their toddler acting out at a nice restaurant, they can simply go out to a Giggles N’ Hugs and let their toddlers frolic and do what toddlers normal do, instead of constantly fussing with them at the table. Trying to force a young child to act like an adult in an upscale restaurant is a nightmare all too many parents are familiar with, and GIGL has elegantly resolved this common problem, with a solution that is the best of both worlds. More importantly, it is unnatural and traumatic for a toddler who doesn’t really understand why they are being forced to act like an adult, to be placed into a high chair and handed adult utensils, then be scolded for wanting to break free and run around.

GIGL has stunned markets in a very short time by bringing forward an execution of its forward-looking casual dining concept, combined with a souped-up Gymboree implementation for the kids, and this disruptive model could really become one of the major players over the next several years here in the industry gobbling up more and more of the $431 billion plus restaurant and bar market. Limited-service restaurants, which are focused more on select menus and the more fluid casual/fast casual dining dollar, continue to dominate the overall restaurant space, at around 55 percent market share. The same kinds of underserved dynamics that have made fast casual so popular in recent years also stand behind the GIGL model, but one look at the landscape is all it takes to realize there is virtually no competition for GIGL, whereas the fast casual market is now extremely crowded by the likes of Chipotle (NYSE: CMG), Panera (NASDAQ: PNRA), and many others. The underserved market dynamics which led to the boom in fast casual have now led to an over-saturated space, where even companies more traditionally focused on retail now offer some kind of micro eatery on the premises, a problem not seen in the very clear niche GIGL is developing.

While there is obvious competition from players like Chuck E. Cheese’s, the overall approach by GIGL to the market is so categorically different that the company should continue to have no problem distinguishing itself as the new kid on the block with fresh ideas, a healthy menu, and healthy, engaging activities for the kids. As opposed to standard fare that families will find elsewhere, like arcade games and soulless ticket redemption games such as skee-ball, which are basically designed to pick the pocket of consumers who are increasingly mindful of every last penny. The fact that GIGL has really hit the ground running since its inception and now plays host to some of the most high profile celebrities in the world, who routinely bring their kids to Giggles N’ Hugs for parties, a play date, or just to have fun while the adults have a nice meal, is a clear indication of where this brand is headed.

Take a closer look, visit the company’s website to learn more www.gigglesnhugs.com

Let us hear your thoughts: Giggles ‘N Hugs, Inc. Message Board

Harvard Apparatus Regenerative Technology is a biotechnology company developing bioengineered organs in order to better address a collection of life-threatening conditions. The company’s development pipeline is headlined by its proprietary second-generation bioengineered organ implant platform, which is currently being developed as a tool to guide the repair of a patient’s own tissue in three unique indications – including diseases of the trachea, bronchi and esophagus. By utilizing a multi-platform approach to clinical development, HART intends to dramatically expand its market opportunity as it continues to explore the development and regulatory pathways for each indication in the coming months.

In recent months, HART’s scientific efforts have been primarily focused on targeting the body response issues encountered during testing of its first-generation trachea product. The company addressed these concerns by utilizing a more elastic material for the device’s scaffold and changing the type of cell that’s seeded onto the scaffold prior to implementation. Through these modifications, HART anticipates achieving improved regenerative response from the body, as well as a more natural restoration of organ function than was observed from its first-generation product. The company, in partnership with the Mayo Clinic, will put these hypotheses to the test in preclinical studies examining its second-generation platform during the fourth quarter of this year.

“We have made tremendous progress in recent months with the development of our second-generation bioengineered organ implant products,” Jim McGorry, chief executive officer of HART, stated in an August news release. “We are poised to make significant further progress over the coming 18 months, including key preclinical and regulatory achievements.”

As of June 30, the company reported a strong cash balance of $10.1 million with no outstanding debt. This favorable balance sheet is expected to play an instrumental role in HART’s ongoing efforts to develop and commercialize its innovative organ implant platform. In order to streamline this progress, the company has built a dedicated internal team of material scientists, engineers and biologists who, in collaboration with the Mayo Clinic and Connecticut Children’s Medical Center, are focused on bringing its products to the patients who need them as quickly as possible.

Currently, most human organs that are surgically implanted come from donors, creating a debilitating market shortage that costs the lives of an average of 22 people in the United States each day, according to the U.S. Department of Health and Human Services. Additionally, immunosuppression following these transplants – which is necessary to insure that the implanted organ isn’t rejected – can lead to serious, potentially deadly infections. By utilizing a patient’s own cells to produce bioengineered organs, HART’s second-generation platform could effectively address both of these limiting factors, allowing the company to establish a sustainable foothold in some of the medical industry’s most critically underserved indications in the near future.

For more information, visit www.harvardapparatusregen.com

Harvard Apparatus Regenerative Technology is a biotechnology company developing bioengineered organs in order to better address a collection of life-threatening conditions. The company’s development pipeline is headlined by its proprietary second-generation bioengineered organ implant platform, which is currently being developed as a tool to guide the repair of a patient’s own tissue in three unique indications – including diseases of the trachea, bronchi and esophagus. By utilizing a multi-platform approach to clinical development, HART intends to dramatically expand its market opportunity as it continues to explore the development and regulatory pathways for each indication in the coming months.

In recent months, HART’s scientific efforts have been primarily focused on targeting the body response issues encountered during testing of its first-generation trachea product. The company addressed these concerns by utilizing a more elastic material for the device’s scaffold and changing the type of cell that’s seeded onto the scaffold prior to implementation. Through these modifications, HART anticipates achieving improved regenerative response from the body, as well as a more natural restoration of organ function than was observed from its first-generation product. The company, in partnership with the Mayo Clinic, will put these hypotheses to the test in preclinical studies examining its second-generation platform during the fourth quarter of this year.

“We have made tremendous progress in recent months with the development of our second-generation bioengineered organ implant products,” Jim McGorry, chief executive officer of HART, stated in an August news release. “We are poised to make significant further progress over the coming 18 months, including key preclinical and regulatory achievements.”

As of June 30, the company reported a strong cash balance of $10.1 million with no outstanding debt. This favorable balance sheet is expected to play an instrumental role in HART’s ongoing efforts to develop and commercialize its innovative organ implant platform. In order to streamline this progress, the company has built a dedicated internal team of material scientists, engineers and biologists who, in collaboration with the Mayo Clinic and Connecticut Children’s Medical Center, are focused on bringing its products to the patients who need them as quickly as possible.

Currently, most human organs that are surgically implanted come from donors, creating a debilitating market shortage that costs the lives of an average of 22 people in the United States each day, according to the U.S. Department of Health and Human Services. Additionally, immunosuppression following these transplants – which is necessary to insure that the implanted organ isn’t rejected – can lead to serious, potentially deadly infections. By utilizing a patient’s own cells to produce bioengineered organs, HART’s second-generation platform could effectively address both of these limiting factors, allowing the company to establish a sustainable foothold in some of the medical industry’s most critically underserved indications in the near future.

For more information, visit www.harvardapparatusregen.com

Stellar Biotechnologies, a leading provider of keyhole limpet hemocyanin (KLH) protein, has made considerable progress toward expanding its production capacity in recent months in order to better accommodate increasing demand for the vital nutrient in the pharmaceutical and biotechnology industries. In July, through a collaboration agreement with Ostiones Guerrero SA de CV, the company secured exclusive rights to the development of a second KLH production site in Baja California, Mexico, effectively bolstering its position as a leader in the sustainable manufacture of the valuable ocean resource. Following this partnership, Stellar’s experienced management team was vocal about the positive implications of establishing itself as the only company with a reliable and scalable supply of KLH.

“We expect demand for reliable sources of KLH to grow, both from our existing partners and the broader biotech industry, as the clinical use of novel immunotherapies increases,” Frank Oates, president and chief executive officer of Stellar, stated in a news release. “We believe this [Ostiones] collaboration will better position Stellar to accelerate its production strategy to accommodate the anticipated growth in the industry.”

Earlier this week, Stellar’s strategy was reaffirmed when its partner, Neovacs, presented promising extended follow-up data from its phase I/IIa clinical trial of IFNα-Kinoid, which is being evaluated for the treatment of systemic lupus erythematosus. Because the company’s KLH protein serves as the carrier molecule in Neovacs’s proprietary immunotherapy technology, these results are anticipated to play a key role in increasing the market demand for Stellar’s sustainable supply of the immune-stimulating protein in the future. In preparation for this increase, the company recently entered into an expanded supply agreement to meet Neovacs’s clinical and commercial requirements moving forward.

“This is an important milestone for Neovacs which, we believe, reinforces the role of KLH as a key carrier molecule in immunotherapy treatments,” continued Oates.

Rising demand for KLH has also had a positive impact on Stellar’s top line results in recent months. During its fiscal quarter ended June 30, the company recorded a 117 percent year-over-year increase in total revenues driven primarily by an increase in product sales resulting from its partners’ continued efforts to advance their respective clinical trials in various underserved therapeutic indications. For prospective shareholders, this performance could foreshadow an opportunity for tremendous growth in the coming months, as Stellar looks to effectively leverage its formidable position as the only company with a reliable and scalable supply of KLH.

For more information, visit www.stellarbiotech.com

Stellar Biotechnologies, a leading provider of keyhole limpet hemocyanin (KLH) protein, has made considerable progress toward expanding its production capacity in recent months in order to better accommodate increasing demand for the vital nutrient in the pharmaceutical and biotechnology industries. In July, through a collaboration agreement with Ostiones Guerrero SA de CV, the company secured exclusive rights to the development of a second KLH production site in Baja California, Mexico, effectively bolstering its position as a leader in the sustainable manufacture of the valuable ocean resource. Following this partnership, Stellar’s experienced management team was vocal about the positive implications of establishing itself as the only company with a reliable and scalable supply of KLH.

“We expect demand for reliable sources of KLH to grow, both from our existing partners and the broader biotech industry, as the clinical use of novel immunotherapies increases,” Frank Oates, president and chief executive officer of Stellar, stated in a news release. “We believe this [Ostiones] collaboration will better position Stellar to accelerate its production strategy to accommodate the anticipated growth in the industry.”

Earlier this week, Stellar’s strategy was reaffirmed when its partner, Neovacs, presented promising extended follow-up data from its phase I/IIa clinical trial of IFNα-Kinoid, which is being evaluated for the treatment of systemic lupus erythematosus. Because the company’s KLH protein serves as the carrier molecule in Neovacs’s proprietary immunotherapy technology, these results are anticipated to play a key role in increasing the market demand for Stellar’s sustainable supply of the immune-stimulating protein in the future. In preparation for this increase, the company recently entered into an expanded supply agreement to meet Neovacs’s clinical and commercial requirements moving forward.

“This is an important milestone for Neovacs which, we believe, reinforces the role of KLH as a key carrier molecule in immunotherapy treatments,” continued Oates.

Rising demand for KLH has also had a positive impact on Stellar’s top line results in recent months. During its fiscal quarter ended June 30, the company recorded a 117 percent year-over-year increase in total revenues driven primarily by an increase in product sales resulting from its partners’ continued efforts to advance their respective clinical trials in various underserved therapeutic indications. For prospective shareholders, this performance could foreshadow an opportunity for tremendous growth in the coming months, as Stellar looks to effectively leverage its formidable position as the only company with a reliable and scalable supply of KLH.

For more information, visit www.stellarbiotech.com

The vital role transfer agents play in today’s increasingly hectic capital markets cannot be overstated. The investment community is reliant on trustworthy, rigorous record keeping by transfer agents when it comes to managing the transfer of securities and providing accurate distinctions regarding specialized transactions such as restricted and freely-tradable shares and proactively preventing unlawful distribution of unregistered securities.

While most transfer agents cater to big companies that have hundreds of thousands of shareholders or more, there are very few specialty shops that have mastered what it takes to fully service SMEs, providing them with the kind of mission-critical, tailored service required to successfully execute tender offers, stock splits, and exchange listing shifts. One of the undisputed masters in this field today is Continental Stock Transfer & Trust, which explicitly caters to companies that have 50,000 or less shareholders, offering round-the-clock access to senior experts and a client-tailored approach.

Continental cultivates strong client relationships, secure in the knowledge that the way to succeed in this arena is to deliver to emerging and midsize clients a full suite of personalized offerings. This key distinction makes Continental Stock Transfer & Trust shine when compared to their competition. From secure 24/7 access to balancing tools such as ControlBook Reporting, a proprietary platform offered to its clients to highly customized extended services, like employee and stock plan administration, dividend reinvestment plans, planning and executing successful annual meetings, EDGAR/XBRL services, or the handling of online material design and distributions.

Because of the specific focus Continental Stock Transfer & Trust has on the emerging markets, the firm has become extremely proficient in IPO fundamentals and thus has a long, successful track record of helping private companies go public. Continental understands the importance of preparing the ground work, such as the assembly of management teams, readying financials for audit, crucial hands-on liaision with the underwriters, and the successful navigation of SEC registration requirements.

A real testament to the company’s storied proficiency in the IPO game is its established reputation as an industry leader in special-purpose acquisition company (SPAC) processing, having handled nearly every SPAC brought to market since 1990 via the same full-spectrum approach that has garnered Continental such accolades for its work in executing IPOs. By providing everything from general transfer, warrant and escrow agent services to distribution of proceeds and tax documents, or the necessary intra depository agent, bank and broker facilitation work, Continental has established itself as the leading provider of SPAC processing.

Look to Continental Stock Transfer & Trust for consistent philosophical dedication to emerging and growth companies.

Look closer by visiting www.continentalstock.com

Cherubim Interests has made advances to solidify its position in the alternative construction industry, real estate development market and controlled environment agriculture sector in recent times. The company has adopted a hybrid business model and inventive market strategy that is uncommon in the real estate and agriculture Industries.

Over the years, Cherubim Interests has strategically identified, developed, managed and invested in single-family, multi-family and mixed-use properties in North America while also dealing with various aspects of real estate development from due diligence, acquisition and planning to construction, renovation and management.

Plus, Cherubim Interests is involved in exploring and engaging in existing and potential opportunities in the controlled environment agriculture sector. The company recently found an entry point into this marketplace by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. With this exclusive license, Cherubim, via its wholly-owned subsidiary, BudCube Cultivation Systems USA, plans to take advantage of the rising demand for grow space that accommodates cannabis and other plant species. How? The company intends to build, install and lease portable, scalable plant cultivation facilities for industrial applications.

Cherubim’s hybrid business model resembles the models used by mini-storage companies who lease secured square footage to individuals and corporations based on need. Under its hybrid format, the company offers two solutions:

1. A single tenant or macro solution
2. A multi-tenant or micro solution

With its single tenant micro solution, Cherubim will enter into an agreement to provide a total cultivation solution to a sole tenant. The company will acquire and develop the land required then deploy a macro solution that meets the square-footage specifications requested by that tenant. On the other hand, with its multi-tenant macro solution, Cherubim Interests will choose a variety of land positions across the U.S. then develop and open a number of hand-picked, secured locations where multiple tenants can lease micro solutions to individuals. Each of these locations will have varying sizes based on market research that relates to their geographical area.

Cherubim’s first step regarding these solutions will be to market test the leasing of units in the legal cannabis industry. In the future though, the company envisions many other practical applications for this technology, especially when considering that severe drought conditions have caused vast food shortages all across the globe.

For more information, visit www.cherubiminterests.com or www.budcube.com

Let us hear your thoughts: Cherubim Interests, Inc. Message Board

Computer and video games have come a long way since the days of arcade classics such as Pac-Man and Frogger, as have those who play them. Widespread adoption of smartphones and other advanced mobile devices has put video games literally at the fingertips of a substantial percentage of the global population. According to a report by Digi-Capital, the gaming industry is expected to surpass $100 billion by 2017, and as much as 60 percent of that revenue is forecast to come from mobile and online gaming.

While industry-leaders such as Electronic Arts (NASDAQ: EA), King (NYSE: KING) and Zynga (NASDAQ: ZNGA) continue to grab market share with original titles costing millions of dollars to develop and market, WRIT Media Group, Inc. (OTCQB: WRIT), through the impending debut of its highly-anticipated Retro Infinity Player gaming software, is strategically positioned to capitalize on this market performance for a fraction of the cost.

When released, the Retro Infinity Player will allow gamers to take a stroll down memory lane without the need to locate old school PCs and gaming consoles. The software will enable gamers to play timeless classics created by legendary video game developers such as Amiga and Atari on a wide variety of modern electronic devices – including mobile phones, tablets, smart TVs and streaming set-top devices. By re-releasing classic video games from the late ‘80s and early ‘90s, WRIT plans to establish a presence in the mobile gaming market while avoiding the risks associated with new game development. Since its licensed titles have already been released, the company has a wealth of market data that should play a key role in helping it determine which games have the highest opportunity for success.

“Retro Infinity’s expertise and niche focus is a key factor in allowing us to bring our Amiga classic titles and other classic brands to these various platforms and to the retro gamer,” Eric Mitchell, president of WRIT, stated in a news release. “We are excited to introduce our best classic titles to both an old and new generation of players.”

Earlier this month, WRIT introduced a crowdfunding campaign designed to raise funds and gauge consumer interest for its upcoming gaming software. As that campaign moves forward, look for the company to continue progressing toward the impending release of the Retro Infinity Player, as well as a selection of classic gaming titles.

For more information about the company, visit www.writmediagroup.com

Let us hear your thoughts: WRIT Media Group, Inc. Message Board

RCI Hospitality Holdings, through its subsidiaries, owns and operates over forty upscale gentlemen’s clubs and restaurants in large markets around the country – including New York City, Miami, Philadelphia, Dallas and Minneapolis. With an unrelenting focus on innovation, the company has created a truly upscale, friendly chain of clubs featuring some of the adult entertainment industry’s most popular and recognizable establishments. This market presence was reaffirmed earlier this month when Tootsie’s Cabaret Miami, the country’s largest adult entertainment complex and a subsidiary of RICK, was named “Overall Gentlemen’s Club of the Year” at the 23rd annual Gentlemen’s Club EXPO in New Orleans.

During its fiscal quarter ending June 30, the company successfully leveraged its established market position in order to achieve strong financial growth. RICK’s total revenues for the period were $35.8 million, which represented a 7.3 percent improvement over the previous year. Among this performance, the company achieved a 200 percent year-over-year increase in sales from its Bombshells restaurant/bar segment, underscoring the effectiveness of its recent acquisition-based growth strategy.

RICK’s management team is led by president and chief executive officer Eric Langan, who has headed the company for more than 15 years. By employing self-motivated managers, adhering to strict cost control, increasing cash flow and promoting maximized shareholder value, Langan has helped transform RICK into a leading consolidator in the expansive gentlemen’s club industry while maintaining a consistent spot on Forbes’s list of America’s 200 Best Small Companies. Moving forward, the company will benefit from his immense leadership experience as it continues to expand into the thriving restaurant industry.

With a full roster of past performers who have eventually joined the illusive ranks of Penthouse Pets and Playboy Playmates, it’s easy to see why RICK has continued to thrive in the adult entertainment market for more than three decades. Look for the company to rely on industry innovation and its experienced management team in order to ensure that its collection of major brands – including Rick’s Cabaret, Vivid Cabaret, Tootsie’s Cabaret, Club Onyx, Jaguars Club, XTC Cabaret and Bombshells – remain fixtures in their respective markets for the foreseeable future.

For more information, visit www.rcihospitality.com

As part of the expansion of its Organic Chewable Juice line, Fresh Promise Foods subsidiary Harvest Soul is exhibiting two new flavors at the Natural Products Expo East 2015 in Baltimore, Maryland, September 17-19, 2015. Berry Banana Fusion and Veggie Beet Fusion are making their debut at the expo, along with original flavors Green Fusion and Tropical Fusion.

Natural Products Expo East is the East Coast’s largest natural, organic and healthy products event, expected to reach record numbers this year, with more than 22,000 attendees and more than 1,800 exhibitors. The event provides Harvest Soul considerable brand and product exposure.

“We’re excited to be at Expo East for the first time and launch our two new chewable juice flavors,” Kevin P. Quirk, Fresh Promise Foods CEO and Harvest Soul president stated in the news release. “We believe kids and adults of all ages will love the taste of both juices and the ingredients have incredible health benefits. One example is beet, which boosts stamina, lowers blood pressure and has anti-cancer properties. I’m also extremely proud that our juices are Non-GMO Project verified, a symbol that tells our consumers that Harvest Soul is committed to only using clean and pure ingredients in our juices.”

Harvest Soul Organic Chewable Juices are a blend of at least 15 fruits and vegetables, along with bits of seeds, nuts and berries to create a flavorful, fiber and protein-packed dose of nutrition. Each Harvest Soul juice is concentrate-free and without added flavors or sugar. Harvest Soul Organic Chewable Juices are sold in 12 ounce bottles. All four flavors, including Berry Banana Fusion, Green Fusion, Tropical Fusion and Veggie Beet Fusion, are available at Whole Foods Market locations and online at www.harvestsoul.com.

What makes Harvest Soul Organic Chewable Juice revolutionary to the juice category is that it promotes chewing, which jump starts digestion. Chewing helps the body break down foods, unlocking beneficial nutrients by releasing enzymes that promote better nutrient absorption. Chewing also helps regulate caloric intake, as it takes more time than drinking, making for a more satisfying experience.

Research has also shown that consumers that predominately rely on fruit and vegetable juices to supply their daily nutrition miss out on the health benefits that come from chewing, as well as forfeit the natural fiber and protein wasted during the juicing process. Harvest Soul Chewable Juices are blended, not pressed, so beneficial fiber is retained.

Visit Harvest Soul throughout the duration of the three-day expo at Booth #8222, and follow the company on Facebook: www.facebook.com/harvestsoul and Twitter: @harvestsoul.

For more information visit www.freshpromisefoods.com

Let us hear your thoughts: Fresh Promise Foods, Inc. Message Board